Ryder SystemNYSE: R

Vancouver, British Columbia--(Newsfile Corp. - November 1, 2024) - Jackpot Digital Inc. (TSXV: JJ) (TSXV: JJ.WT.C) (OTCQB: JPOTF) (FSE: LVH3) (the "Company" or "Jackpot"), a leading manufacturer of electronic multiplayer dealerless poker tables, is pleased to announce it has placed an order with its manufacturing partner for 100 additional Jackpot Blitz® dealerless electronic poker tables (ETGs). Production of the units will begin immediately.

Pilot John International(R) (PJi(R)) is thrilled to announce an exciting new partnership with Teledyne Battery Products to provide its customers with trusted Gill aircraft batteries and accessories. Greenville, North Carolina--(Newsfile Corp. - November 1, 2024) - Pilot John International ® (PJi®) is thrilled to announce an exciting new partnership with Teledyne Battery Products to provide its customers with trusted Gill aircraft batteries and accessories.

R now expects its 2024 adjusted earnings guidance between $11.90 and $12.10 per share compared with the prior guided view of $11.90-$12.40.

CLEVELAND, OH / ACCESSWIRE / October 28, 2024 / Mace Security International (OTCQB:MACE) today announced that, due the recently announced Agreement and Plan of Merger, the previously announced 2024 Annual Meeting of Shareholders is postponed and will be rescheduled if and as necessary pending the potential merger transaction contemplated by the Agreement and Plan of Merger. Separately, a Special Meeting of Shareholders will be called to vote on the Agreement and Plan of Merger.

Additional ACG presentation to focus on impact of Xifaxan on OHE rehospitalizations LAVAL, QC / ACCESSWIRE / October 27, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced that results of an analysis of Xifaxan® (rifaximin) monotherapy will be presented during a Presidential Plenary Session of The American College of Gastroenterology® 2024 Annual Scientific Meeting taking place October 25-30 in Philadelphia, PA. This post hoc analysis of data from two randomized trials evaluated the efficacy of Xifaxan monotherapy compared to lactulose monotherapy for risk reduction of overt hepatic encephalopathy (OHE) recurrence and all-cause mortality.

Ryder System, Inc. (NYSE:R ) Q3 2024 Earnings Conference Call October 24, 2024 11:00 AM ET Company Participants Calene Candela – Vice President, Investor Relations Robert Sanchez – Chairman and Chief Executive Officer John Diez – Executive Vice President and Chief Financial Officer Tom Havens – President, Fleet Management Solutions Steve Sensing – President, Supply Chain Solutions and Dedicated Transportation Solutions Conference Call Participants Jordan Alliger – Goldman Sachs Christyne McGarvey – Morgan Stanley Jeff Kauffman – Vertical Research Partners Scott Group – Wolfe Research Brian Ossenbeck – JPMorgan Daniel Imbro – Stephens Operator Good morning, and welcome to the Ryder System Third Quarter 2024 Earnings Release Conference Call. All lines are in a listen-only mode until after the presentation.

The headline numbers for Ryder (R) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ryder (R) came out with quarterly earnings of $3.44 per share, beating the Zacks Consensus Estimate of $3.39 per share. This compares to earnings of $3.58 per share a year ago.

Ryder (R) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.